Free shipping on orders from 160 €from 160 € 3-vial Retatrutide 30 mg pack at 150 € See the packs
ORDER

COMPARATIVE GUIDE

Research on GLP-1 peptides has evolved rapidly in recent years: from the mono-agonist Semaglutide to the dual-agonist Tirzepatide, and now to the triple-agonist Retatrutide. Each generation targets more metabolic receptors, amplifying the effects on fat loss and metabolic remodeling.

This guide compares the three molecules based on published clinical trial data, to help researchers understand the mechanistic differences and choose the peptide best suited to their protocols.

Comparative table: Retatrutide vs Tirzepatide vs Semaglutide

CriteriaSemaglutideTirzepatideRetatrutide
Targeted receptorsGLP-1RGLP-1R + GIPRGLP-1R + GIPR + GcgR
Weight loss (pivotal trial)~15% (STEP-1, 68 weeks)~22% (SURMOUNT-1, 72 weeks)~24% (Phase 2, 48 weeks)
Half-life~7 days~5 days~6 days
AdministrationSC weeklySC weeklySC weekly
Clinical stage (2026)Approved (FDA/EMA)Approved (FDA/EMA)Phase 3 in progress (NCT06859268)
Effect on fat massStrongVery strongVery strong + hepatic lipolysis
Glycemic effectStrongStrongStrong (+ glucagon effect)
Research availabilityLimitedLimited✓ MyPeptide.eu

Semaglutide: the reference GLP-1 monoagonist

Semaglutide (Ozempic®, Wegovy®) is a selective GLP-1 receptor agonist with a half-life of ~7 days obtained by conjugation to a C18 fatty acid chain. In the STEP-1 trial, it demonstrated an average body weight reduction of 14.9% over 68 weeks in non-diabetic obese patients. (Wilding JPH et al., 2021, PMID 33567185).

Main mechanism: activation of GLP-1R in the hypothalamus (reduction of appetite), pancreatic beta cells (glucose-dependent insulin secretion) and gastric mucosa (slowing of gastric emptying).

Tirzepatide: the GLP-1/GIP dual-agonist

Tirzepatide (Mounjaro®, Zepbound®) simultaneously activates GLP-1R and GIPR receptors. The potentiation of both incretin pathways explains its superiority over Semaglutide: in the SURMOUNT-1 trial (72 weeks), the maximum dose of 15 mg produced a weight reduction of 22.5%. (Jastreboff AM et al., 2022, PMID 35658024).

The GIPR receptor plays a complementary role in the regulation of adipogenesis and directly potentiates the central anorexigenic effect of GLP-1R (Drucker DJ et al., 2023, PMID 36976349).

Retatrutide (LY3437943): the GLP-1/GIP/Glucagon triple agonist

Retatrutide is the first GLP-1R/GIPR/GcgR triple agonist to reach Phase 3 clinical trials. In Phase 2 (48 weeks, n=338), the 12 mg dose produced a mean body weight reduction of 24.2%—the highest ever observed for weekly treatment over this duration. (Jastreboff AM et al., 2023, PMID 37366315).

The addition of glucagon agonist (GcgR) provides three additional effects compared to Tirzepatide:

  • Increased energy expenditure basal (thermogenesis)
  • Increased hepatic lipolysis — reduction of hepatic steatosis (MASH) (Briand F et al., 2026, PMID 41741376)
  • Reduction of de novo lipogenesis

Its molecular mass is approximately 4,720 Da, with a C18 fatty acid chain conferring a half-life of ~6 days (weekly administration). Retatrutide is currently in Phase 3 (TRIUMPH-1 trial, NCT06859268) for the indication of obesity.

Which peptide for your research protocol?

The choice depends on the research question:

  • Study of specific GLP-1R mechanisms → Semaglutide (selective agonist)
  • GLP-1 + GIP potentiation, incretin comparison → Tirzepatide
  • Triple-agonist effect, metabolic remodeling, hepatic steatosis → Retatrutide
Available for search
Retatrutide R3 10mg & 20mg
Triple agonist GLP-1/GIP/Glucagon. HPLC purity 99%+ certified by Janoshik. COA per batch.
Buy Reta R3 10 mg — €59.90

Frequently asked questions

Retatrutide vs Semaglutide: what's the difference?

Semaglutide is an approved mono-GLP-1 agonist (Ozempic, Wegovy). Retatrutide is a triple GLP-1/GIP/Glucagon agonist still in Phase 3 trials, with a weight loss of approximately 24% in Phase 2, compared to approximately 15% for Semaglutide in its own trials.

Retatrutide vs Tirzepatide: which is more effective?

Tirzepatide (Mounjaro) is an approved dual GLP-1/GIP agonist, with approximately 21% weight loss in the SURMOUNT-1 trial. Retatrutide adds glucagon agonism for approximately 24% in Phase 2, but is not yet approved.

Where can I find Retatrutide for scientific research?

MyPeptide.eu offers lyophilized Retatrutide R3 (10 mg and 20 mg) for laboratory research use only, with HPLC purity ≥ 99% certified by Janoshik; reports for each batch are published on the certificates of analysis page. To compare suppliers and prices per milligram, see our retatrutide supplier in France page.

Leave a comment

Your email address will not be published. Required fields are indicated with an asterisk (*). *

FRENDEITESPTNLPLSV
Back to top